Of the estimated 168,811 men who will be treated for prostate cancer (PC) with curative intent in 2006,>30% will ultimately experience disease recurrence, metastasis, and die of PC. There is substantialuncertainty, however, in predicting which individual patients will have adverse outcomes based on bothclinical presentation and pathological features. In the previous proposal, we hypothesized the complexity ofthe PC progression process could be explained by genetic variants that confer susceptibility to moreaggressive or to lethal PC. That is, subtle changes in transcription,translation or the function of geneproducts due to inherited genetic variants may modify tumor behavior. In the current proposal, we willexpand our investigation into whether allelic variation plays a role in metastatic efficiency (i.e.. the ability of atumor to spread or recur), with the following specific aims: 1) Evaluate the association of genetic polymorphisms in candidate genes with PC-specific mortality anddisease recurrence/progression using two population-based cohorts of PC patients (follow-up mean=10.4yrs.; range 5-17 yrs.). As part of the initial SPORE proposal a panel of 384 single nucleotide polymorphisms(SNPs) in candidate genes associated with PC pathways (e.g., androgens) has been genotyped in Cohort 1(n=630). For the current proposal, interesting SNPs (i.e., p<0.15 in relation to PC-specific death from Coxmodels) from Cohort 1 will be genotyped in patient Cohort 2 (n=840) for confirmation. SNPs that arevalidated will be examined with outcomes in both cohorts; 2) Examine tagSNPs in PC metastasis-suppressor genes (e.g., KAI1, MAPKK4) in relation to PCoutcomesas defined in Aim 1 in all patients with DNA from both cohorts (n=1,470); and, 3) Evaluate genotype-phenotype associations within the combined cohort of PC patients to identify SNPsthat are correlated with more aggressive or less aggressive disease features. These analyses will considerwhether individual SNPs, haplotypes (tagSNPs within candidate genes), or groups of SNPs in candidategenes in defined pathways are independently associated with PC aggressiveness. We anticipate this study will provide new insights into genetic pathways and mechanisms that determinemetastatic potential, pushing PC toward its lethal phenotype. Knowledge of metastasis-modifier alleles mayhelp identify subsets of PC patients at higher risk for adverse outcomes, those who would benefit most fromtailored individual therapies (e.g., early adjuvant therapy, or expectant management), from heightenedsurveillance for recurrence/progression, and early interventions aimed at reducing PC deaths.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097186-06
Application #
7314863
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-09-14
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$186,895
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501
Inoue, Lurdes Y T; Lin, Daniel W; Newcomb, Lisa F et al. (2018) Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med 168:1-9
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Levesque, Christine; Nelson, Peter S (2018) Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harb Perspect Med 8:
Barnard, Monique; Quanson, Jonathan L; Mostaghel, Elahe et al. (2018) 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183:192-201
Ganaie, Arsheed A; Beigh, Firdous H; Astone, Matteo et al. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models. Clin Cancer Res 24:6421-6432
Schweizer, Michael T; Haugk, Kathleen; McKiernan, Jožefa S et al. (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One 13:e0198389
Peacock, James W; Takeuchi, Ario; Hayashi, Norihiro et al. (2018) SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med 10:219-238
Pollan, Sara G; Huang, Fangjin; Sperger, Jamie M et al. (2018) Regulation of inside-out ?1-integrin activation by CDCP1. Oncogene 37:2817-2836
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14

Showing the most recent 10 out of 400 publications